Selective serotonin reuptake inhibitor discontinuation syndrome in children: Six case reports

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 3, 2002, Pages 188-197

  Diler, Rasim Somer ^a,b   Avci, Ayse ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Adverse effect; Child; Discontinuation; Fluvoxamine; Paroxetine; Psychopharmacology; Selective serotonin reuptake inhibitor; Sertraline; Withdrawal

Indexed keywords

FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SELECTIVE SEROTONIN REUPTAKE INHIBITOR DISCONTINUATION SYNDROME; VERTIGO; WITHDRAWAL SYNDROME;

EID: 0036217198     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80025-X     Document Type: Article

References (37)

1. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review
2. Physical symptoms associated with paroxetine discontinuation
3. Serotonin reuptake inhibitor withdrawal
4. Withdrawal syndromes after paroxetine and sertraline discontinuation
5. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors
6. Paroxetine withdrawal syndromes
7. Fluvoxamine withdrawal syndrome
8. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
9. Selective serotonin reuptake inhibitor discontinuation syndrome: Proposed diagnostic criteria
10. Prospective study of scheduled withdrawal from nortriptyline in children and adolescents
11. Current knowledge of medications for the treatment of childhood anxiety disorders
12. Multicenter open-label sertraline study in adolescent outpatients with major depression
13. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression
14. Treatment of ADHD with fluoxetine: A preliminary trial
15. Treatment of elective mutism with fluoxetine: A double-blind, placebo-controlled study
16. Fluoxetine for childhood anxiety disorders
17. Open-label trial of paroxetine in children with obsessive-compulsive disorder
18. Nontricyclic antidepressants: Current trends in children and adolescents
19. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial
20. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial
21. Paroxetine in children with major depressive disorder: An open trial
22. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: A randomized, controlled, multicenter trial
23. Effects of paroxetine in depressed adolescents
24. Long-term experience with citalopram in the treatment of adolescent OCD
25. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder
26. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial
27. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998
28. Withdrawal symptoms associated with paroxetine discontinuation in a nine-year old boy
29. Clinical management of antidepressant discontinuation
30. Selective serotonin reuptake inhibitors discontinuation syndromes
31. A review of the metabolism and pharmacokinetics of paroxetine in man
32. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders
33. Paroxetine pharmacokinetics in depressed children and adolescents
34. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents
35. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: Pharmacokinetics, tolerability, and efficacy
36. Antidepressant withdrawal phenomena
37. Antidepressant withdrawal syndromes: Phenomenology and pathophysiology